Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BECTON, DICKINSON AND COMPANY

(BDX)
  Report
Delayed Nyse  -  04:00 2022-10-05 pm EDT
236.83 USD   -0.06%
10/03Becton Dickinson And : BD Names Eric Borin President of Medication Delivery Solutions
PU
09/27Becton, Dickinson and Co. Currently Down Nine Consecutive Days, on Pace for Longest Losing Streak Since December 1988 -- Data Talk
DJ
09/27Becton, Dickinson Launches New Cloud-Based Software Solution
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Becton Dickinson and : Statement of Changes in Beneficial Ownership - Form 4

08/11/2022 | 04:50pm EDT
Ownership Submission
FORM 4
Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287Expires:January 31, 2005Estimated average burden hours per response...0.5
1. Name and Address of Reporting Person *
Polen Thomas E Jr
2. Issuer Name and Ticker or Trading Symbol
BECTON DICKINSON & CO [BDX]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
Executive Vice President /
(Last) (First) (Middle)
C/O BECTON, DICKINSON AND COMPANY , 1 BECTON DRIVE
3. Date of Earliest Transaction (Month/Day/Year)
(Street)
FRANKLIN LAKES NJ 07417
4. If Amendment, Date Original Filed(Month/Day/Year)
6. Individual or Join/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code 4. Securities Acquired (A) or Disposed of (D) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) 6. Ownership Form: Direct (D) or Indirect (I) 7. Nature of Indirect Beneficial Ownership
Code V Amount (A) or (D) Price
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code 5. Number of Derivative Securities Acquired (A) or Disposed of (D) 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security 8. Price of Derivative Security 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) 11. Nature of Indirect Beneficial Ownership
Code V (A) (D) Date Exercisable Expriation Date Title Amount or Number of Shares
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Polen Thomas E Jr
C/O BECTON, DICKINSON AND COMPANY
1 BECTON DRIVE
FRANKLIN LAKES, NJ07417


Executive Vice President
Signatures
Gary DeFazio, by power of attorney for Thomas E. Polen, Jr. 2022-08-11
**Signature of Reporting Person Date
Explanation of Responses:
(*) If the form is filed by more than one reporting person, see Instruction 5(b)(v).
(**) Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $260.00 through $260.03. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. This transaction was made pursuant to a 10b5-1 plan entered into on May 12, 2022.
(2) Direct holdings reflect adjustments made in connection with the spin-off of Embecta Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person.
(3) Award terms reflect adjustments made in connection with the spin-off of Embecta Corp.
(4) The stock appreciation rights vest in four annual installments beginning November 26, 2016.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Disclaimer

BD - Becton, Dickinson and Company published this content on 11 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 August 2022 20:39:35 UTC.


© Publicnow 2022
All news about BECTON, DICKINSON AND COMPANY
10/03Becton Dickinson And : BD Names Eric Borin President of Medication Delivery Solutions
PU
09/27Becton, Dickinson and Co. Currently Down Nine Consecutive Days, on Pace for Longest Los..
DJ
09/27Becton, Dickinson Launches New Cloud-Based Software Solution
MT
09/27BD Launches State-of-the-Art Cloud Software Solution to Streamline Flow Cytometry Resea..
PR
09/27BD Launches Cloud Software Solution to Streamline Flow Cytometry Research
CI
09/26Becton, Dickinson, CerTest Biotec Launch Research-Use-Only Monkeypox Assay
MT
09/26BD, CerTest Biotec Announce US Commercial Launch of Monkeypox Assay
PR
09/26BD, Certest Biotec Announce US Commercial Launch of Monkeypox Assay
CI
09/23Becton Dickinson & Co : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, F..
AQ
09/23Medical device makers see little impact from Fiona on Puerto Rico operations
RE
More news
Analyst Recommendations on BECTON, DICKINSON AND COMPANY
More recommendations
Financials (USD)
Sales 2022 18 853 M - -
Net income 2022 1 866 M - -
Net Debt 2022 13 443 M - -
P/E ratio 2022 34,6x
Yield 2022 1,60%
Capitalization 67 583 M 67 583 M -
EV / Sales 2022 4,30x
EV / Sales 2023 4,11x
Nbr of Employees 75 000
Free-Float 77,9%
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMPANY
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 236,97 $
Average target price 278,08 $
Spread / Average Target 17,3%
EPS Revisions
Managers and Directors
Thomas E. Polen Chairman, President & Chief Executive Officer
Christopher J. DelOrefice Chief Financial Officer & Executive Vice President
William R. Sigmund Chief Medical Officer & Executive Vice President
Elizabeth McCombs Senior Vice President-Research & Development
Joseph M. Smith Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
BECTON, DICKINSON AND COMPANY-3.58%67 583
ABBOTT LABORATORIES-26.76%180 516
MEDTRONIC PLC-18.32%112 313
HOYA CORPORATION-14.49%36 225
DEXCOM, INC.-32.23%35 713
SARTORIUS STEDIM BIOTECH-27.45%32 153